Research programme: DNA polymerase inhibitors - Medivir
Alternative Names: Leukotide programme - MedivirLatest Information Update: 28 Dec 2021
At a glance
- Originator Medivir AB
- Class Antineoplastics
- Mechanism of Action DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for research development in Haematological-malignancies in Sweden
- 08 Nov 2017 Early research in Haematological malignancies in Sweden (unspecified route)